D. Voliotis
Impact in
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
-
- Cancer Mechanisms and Therapy
Papers in
- Hepatology 23
- Hepatocellular Carcinoma Treatment and Prognosis 22
-
- Melanoma and MAPK Pathways 6
- Co-authors
- M. Moscovici (13 shared papers)Dirk Strumberg (8 shared papers)Josep M. Llovet (14 shared papers)Jordi Bruix (13 shared papers)Jean‐Luc Raoul (9 shared papers)M. E. Scheulen (6 shared papers)Vincenzo Mazzaferro (5 shared papers)S. Seeber (4 shared papers)
- Journals
- Journal of Clinical Oncology (19 papers)Journal of Hepatology (5 papers)Annals of Oncology (4 papers)European Journal of Cancer (3 papers)Cancer Research (2 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
D. Voliotis
47 papers receiving 2.9k citations
D. Voliotis's Hit Papers
Peers
Comparison fields: 5 of 86
- Hepatology 1.4k
- Pathology and Forensic Medicine 666
- Oncology 953
- Cancer Research 451
- Hematology 312
Countries citing papers authored by D. Voliotis
This map shows the geographic impact of D. Voliotis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Voliotis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Voliotis more than expected).
Fields of papers citing papers by D. Voliotis
This network shows the impact of papers produced by D. Voliotis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Voliotis. The network helps show where D. Voliotis may publish in the future.
Co-authors
The 25 scholars most cited alongside D. Voliotis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors Hit paper breakdown → | 2004 | 694 |
| 2 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial Hit paper breakdown → | 2012 | 656 |
| 3 | 2005 | 322 | |
| 4 | 2012 | 222 | |
| 5 | 2007 | 163 | |
| 6 | 2006 | 115 | |
| 7 | 2012 | 102 | |
| 8 | 2002 | 92 | |
| 9 | 2006 | 87 | |
| 10 | Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. | 2011 | 79 |
| 11 | 2008 | 45 | |
| 12 | 2007 | 44 | |
| 13 | 2005 | 38 | |
| 14 | 2007 | 24 | |
| 15 | 2010 | 22 | |
| 16 | 2004 | 21 | |
| 17 | 2003 | 21 | |
| 18 | 2021 | 20 | |
| 19 | 2008 | 20 | |
| 20 | 2003 | 19 |
About D. Voliotis
D. Voliotis is a scholar working on Hepatology, Molecular Biology, Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 48 papers that have together received 3.0k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Colorectal Cancer Treatments and Studies (8 papers), Cancer, Lipids, and Metabolism (8 papers), Liver Disease Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (7 papers), Melanoma and MAPK Pathways (6 papers), Cancer Mechanisms and Therapy (6 papers) and Hepatitis B Virus Studies (5 papers). The work is most often cited by research in Hepatology (1.4k citations), Pathology and Forensic Medicine (666 citations), Oncology (953 citations), Cancer Research (451 citations) and Hematology (312 citations). D. Voliotis has collaborated with scholars based in Germany, United States and France. Frequent co-authors include M. Moscovici, Dirk Strumberg, Josep M. Llovet, Jordi Bruix, Jean‐Luc Raoul, M. E. Scheulen, Vincenzo Mazzaferro, S. Seeber, Heike Richly and E. Brendel. Their work appears in journals such as Journal of Clinical Oncology, Journal of Hepatology, Annals of Oncology, European Journal of Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.